Crypto EcoBlog
CoinspeakerJohnson & Johnson Reports Better than Expected Q2 2023 Earnings, JNJ Shares Up Slightly The pharmaceutical segment reported the highest sales with about $13.71 billion, followed by MedTech with a total sales of about $7.78 billion, and the remaining accrued from the consumer health segment. Johnson & Johnson Reports Better than Expected Q2 2023 Earnings, JNJ Shares Up Slightly
Read More »5 Coronavirus Stocks to Look Out For as COVID-19 Spread Continues
A few stocks, including some of the ones below, are being classified as COVID-19 stocks because of their potential to rise even as the pandemic worsens.Apart from the obvious health effects, the current coronavirus pandemic has already depleted financial markets all over the world. As the outbreak continues to spread and the world records a lot more confirmed cases, these economic effects are also going to continue. Many companies are already recording heavy losses and many of the world’s...
Read More »JNJ, MRNA Stocks Down Around 1.5%, J&J and Moderna to Produce Possible COVID-19 Vaccine
The U.S government has partnered Johnson & Johnson and Moderna to facilitate the production of the possible COVID-19 vaccine in large quantities.The government of the United States of America alongside Johnson & Johnson (NYSE: JNJ) and Moderna Inc (NASDAQ: MRNA) have partnered to produce in more substantial amounts possible vaccine for COVID-19 before the real vaccines hit the market. As per report, the U.S. government is also working to partner with not lesser than two other...
Read More »Johnson & Johnson Stock Up 7%, Human Testing of Coronavirus Vaccine to Begin by September
Johnson & Johnson after the announcement of the test of its coronavirus vaccine, JNJ stock has continued to surge, rising over 7%.Multinational pharmaceutical firm Johnson & Johnson (NYSE: JNJ) on Monday announced that human trial of its experimental vaccine for ravaging coronavirus will start September and would be ready for emergency use authorization early next year.After Johnson and Johnson made the announcement, the firm’s JNJ stock has continued to surge, rising over 7%.Johnson...
Read More »Johnson & Johnson (JNJ) Stock Down 2% Today, Coronavirus Vaccine Not Ready Until Year-End
Johnson & Johnson (NYSE: JNJ) stock lost 5.64% on Friday and is 2.33% down today. The company’s CEO Alex Gorsky reassured that the company will have important data by the end of the year to offer a coronavirus vaccine.In the race for the search of a coronavirus vaccine is an American multinational corporation, Johnson & Johnson (NYSE: JNJ). However, things are not all rosy for its stock market which has been falling for the past two months. As a result, all the gains made from late...
Read More »